Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
LH - Labcorp Holdings Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$328.50
DETAILS
HIGH:
$355.00
LOW:
$300.00
MEDIAN:
$329.00
CONSENSUS:
$328.50
DOWNSIDE:
0.95%
Stock News
Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity
Enhanced digital experience designed to improve visibility, simplify workflows and support faster decision-making BURLINGTON, N.C., Aug. 31, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect™, the company's portfolio of clinical trial services, data and technology that enhances and accelerates delivery.
Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
BURLINGTON, N.C., Aug. 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept.
Should You Continue to Hold Labcorp Stock in Your Portfolio?
LH's specialty-testing expansion, strategic partnerships and buybacks support growth, while reimbursement and cost pressures pose risks.
Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings Measures phosphorylated Tau 217 (pTau-217), an indicator of amyloid pathology and a hallmark of Alzheimer's disease Intended for individuals 55 and older with signs, symptoms or complaints of cognitive decline BURLINGTON, N.C., Aug. 24, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA).
Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health
Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health Centers BURLINGTON, N.C. and BETHESDA, Md.
Labcorp (NYSE:LH) Sets New 12-Month High – Time to Buy?
Shares of Labcorp Holdings Inc. (NYSE: LH - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $326.89 and last traded at $323.18, with a volume of 786484 shares changing hands. The stock had previously closed at $318.13. Analysts Set New Price Targets Several research analysts
Labcorp to Host Investor Day on September 10, 2026
BURLINGTON, N.C., Aug. 17, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m.
Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million
The CEO liquidated 4,669 shares at a price of $320.37 per share, totaling ~$1.5 million on August 11, 2026. The transaction resulted in a 4% reduction of the executive's total equity holdings in the company.
Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?
LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.
Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
Labcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapies Supports access to targeted treatment options for the deadliest form of skin cancer BURLINGTON, N.C., Aug. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.
Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation
LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.
Here's Why Labcorp Holdings (LH) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.
Labcorp Q2 Earnings Call Highlights
Labcorp NYSE: LH reported second-quarter 2026 revenue growth, margin expansion and higher adjusted earnings, prompting the laboratory services company to raise the midpoint of its full-year revenue and adjusted EPS guidance.
Labcorp Holdings Inc. (LH) Q2 2026 Earnings Call Transcript
Labcorp Holdings Inc. (LH) Q2 2026 Earnings Call Transcript
LH Stock Down Despite Q2 Earnings and Revenue Beat, Margins Rise
Labcorp's Q2 earnings and revenues surpass estimates, margins expand, and its 2026 outlook is raised, but shares fall 6% in pre-market trading.
Labcorp (LH) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Labcorp Holdings (LH) Surpasses Q2 Earnings and Revenue Estimates
Labcorp Holdings (LH) came out with quarterly earnings of $4.99 per share, beating the Zacks Consensus Estimate of $4.79 per share. This compares to earnings of $4.35 per share a year ago.
Price Targets
Labcorp price target raised to $355 from $320 at Mizuho
$355.00
(was $319.17)
Ann Hynes
·
Mizuho Securities
Labcorp price target raised to $338 from $308 at Morgan Stanley
$338.00
(was $308.64)
Morgan Stanley
Labcorp price target raised to $306 from $276 at Deutsche Bank
$306.00
(was $308.69)
Deutsche Bank
Labcorp price target raised to $352 from $338 at Baird
$352.00
(was $315.53)
Robert W. Baird
Labcorp price target raised to $320 from $290 at Barclays
$320.00
(was $315.82)
Barclays
Labcorp price target raised to $334 from $332 at Baird
$334.00
(was $255.97)
Eric Coldwell
·
Robert W. Baird
Labcorp price target raised to $300 from $280 at Evercore ISI
$300.00
(was $274.72)
Evercore ISI
Labcorp price target raised to $300 from $270 at Piper Sandler
$300.00
(was $285.30)
David Westenberg
·
Piper Sandler
Labcorp price target raised to $326 from $313 at Baird
$326.00
(was $276.67)
Robert W. Baird
Labcorp price target raised to $313 from $307 at Baird
$313.00
(was $259.18)
Robert W. Baird
Labcorp price target lowered to $320 from $325 at UBS
$320.00
(was $253.74)
Kevin Caliendo
·
UBS
Labcorp price target lowered to $304 from $313 at Baird
$304.00
(was $259.69)
Robert W. Baird
Leerink on Laboratory Corporation of America (LH): 'Sell-off Unwarranted'
$342.00
(was $261.62)
Michael Cherny
·
Leerink Partners
Labcorp price target raised to $325 from $305 at UBS
$325.00
(was $285.93)
UBS
Labcorp price target raised to $320 from $285 at Mizuho
$320.00
(was $283.71)
Ann Hynes
·
Mizuho Securities
Labcorp price target raised to $320 from $310 at Truist
$320.00
(was $278.42)
Truist Financial
Labcorp price target raised to $305 from $300 at Evercore ISI
$305.00
(was $279.44)
Evercore ISI
Labcorp price target raised to $290 from $275 at Barclays
$290.00
(was $279.06)
Barclays
Labcorp price target raised to $311 from $302 at Baird
$311.00
(was $276.11)
Robert W. Baird
Labcorp price target raised to $305 from $282 at UBS
$305.00
(was $264.96)
Kevin Caliendo
·
UBS